Two MS Drugs Go Head-to-Head: What a Major New Trial Means for Patients in Kent

A landmark phase 3 clinical trial published in the New England Journal of Medicine has directly compared two widely used multiple sclerosis treatments for the first time, with findings that could shape how the condition is managed across the UK.

A Condition That Touches Many Lives Here

Multiple sclerosis — MS for short — is a condition where the immune system mistakenly attacks the protective covering of nerve fibres in the brain and spinal cord. It affects around 130,000 people across the UK, and for those living with it in Kent, every development in treatment research matters. Relapses can mean days or weeks of worsening symptoms: fatigue, difficulty walking, problems with vision. So when a major trial compares two of the most commonly prescribed drugs directly, it’s worth paying close attention.

The Trial That’s Got Neurologists Talking

The New England Journal of Medicine — one of the most respected medical journals in the world — has published results from the OVERLORD-MS trial, a phase 3 study comparing rituximab and ocrelizumab in people newly diagnosed with relapsing MS. Phase 3 is the gold standard of clinical research: large-scale, rigorous, and designed to give doctors reliable answers about how treatments perform against each other in real-world conditions.

Both drugs belong to a class called anti-CD20 therapies. In plain English, they work by targeting and depleting a type of immune cell — B cells — that plays a role in driving MS-related inflammation. Ocrelizumab is already NHS-approved for relapsing MS under the brand name Ocrevus. Rituximab, by contrast, has been used off-label in some countries for MS, meaning it’s prescribed outside its original licensed use.

The NEJM posted about both the trial results and an accompanying review article on advances in MS treatment, signalling just how much momentum there is in this area of neurology right now.

Why This Comparison Matters

Until now, there hasn’t been a direct head-to-head phase 3 comparison of these two drugs in newly diagnosed relapsing MS patients. Doctors have had to rely on indirect comparisons — essentially reading between the lines of separate studies. A direct trial gives clinicians far clearer guidance.

Cost is also a real-world factor. Rituximab is an older drug and, in some health systems, considerably cheaper than ocrelizumab. If the two drugs prove similarly effective, that has consequences for NHS prescribing decisions and, ultimately, for how quickly patients can access treatment.

What Comes Next

The full findings are available through the New England Journal of Medicine. The accompanying review article on advances in MS also offers broader context on where the field is heading — from earlier diagnosis to newer treatment approaches being explored in clinical settings.

—

Key Takeaways

• The OVERLORD-MS phase 3 trial, published in the New England Journal of Medicine, is the first direct head-to-head comparison of rituximab and ocrelizumab in newly diagnosed relapsing MS patients
• Both drugs are anti-CD20 therapies that work by reducing immune cells linked to MS-related inflammation — ocrelizumab is NHS-approved for relapsing MS, while rituximab has been used off-label in some settings
• The results could influence NHS prescribing decisions and patient access to treatment across the UK, including here in Kent

What This Means for Kent Residents

If you or someone you know is living with relapsing MS in Kent, this kind of research is directly relevant to the conversations you might have with your neurologist or GP. NHS Kent and Medway Integrated Care Board oversees local neurology services, and trials like OVERLORD-MS feed into the national guidance that shapes what treatments are available on the NHS. It’s always worth asking your specialist whether new published evidence affects your current treatment plan — and never adjust or stop medication without speaking to your doctor first. For general health questions, NHS 111 is available around the clock, and the MS Society helpline (0808 800 8000) offers free, confidential support for anyone affected by multiple sclerosis.